High prices for drugs for rare diseases have introduced uncertainties from payers around whether a medication’s value justifies its price.
Model-based meta-analysis is a quantitative framework that uses PK/PD and statistical modeling of external data to inform drug development decisions.
The Certara Quantitative Systems Toxicology & Safety (QSTS) Pharma Consortium: Overview and Invitation to Join
Quantitative Systems Toxicology Approach Integrates Simcyp PBPK and Core Hepatocyte Metabolism: a Case Study with Valproic Acid
Organ-on-chip systems aim to recapitulate human physiology in vitro and hold the promise to revolutionize drug development.
Quantitative description of the physiological changes in diseased skin and their incorporation into Physiologically Based Pharmacokinetic Models.
A comparison of two model reduction methodologies for a QSP bone biology system with denosumab dosing
QSP Modelling of Neurodegenerative Chronic Diseases and Brain Biomarkers: Adding the Effect of Ageing on Brain Volume
Clinical validation of a quantitative systems pharmacology (QSP) model for nerve-growth factor (NGF) therapies
This webinar discussed which pharmaceutical payer strategies work and which don’t in our rapidly changing regulatory and reimbursement world.